Positive one-year data for subcutaneous Ocrevus

Swiss pharma giant Roche (ROG: SIX) today released new data from the Phase III OCARINA II study (S31.006) of Ocrevus (ocrelizumab), an investigational twice-yearly, 10-minute subcutaneous (SC) injection.

Ocrevus, which generated sales of over $7 billion in 2023, is currently approved as an IV infusion to treat both relapsing multiple sclerosis (M) and primary progressive MS in adults.

Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential benefits of this investigational formulation. Treatment with Ocrevus SC led to rapid and sustained B-cell depletion in the blood.